0.06% -0.0408

Supernus Pharmaceuticals Inc (SUPN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SUPN? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Supernus Pharmaceuticals Inc

Healthcare (1118)

301-838-2500

9715 KEY WEST AVENUE, ROCKVILLE, MD

@Supernus_Pharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SUPN's Discussions on Twitter

Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SUPN Supernus Pharmaceuticals Inc	50.32	2.91B	718.95M	-38.55M	45.99M	-0.6839
TAK Takeda Pharmaceutical Co Adr	17.82	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	114.58	48.74B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.03	44.85B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.67	34.12B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	540.33	23.35B	3.13B	1.27B	1.12B	26.39

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-09	Hochstufung	Piper Sandler	Neutral → Overweight
2025-07-30	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-02-19	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2025-01-06	Eingeleitet	Cantor Fitzgerald	Overweight
2024-09-11	Herabstufung	Piper Sandler	Overweight → Neutral
2023-01-03	Fortgesetzt	Jefferies	Buy
2021-12-01	Fortgesetzt	Jefferies	Buy
2021-04-13	Hochstufung	Jefferies	Hold → Buy
2020-06-16	Hochstufung	Piper Sandler	Neutral → Overweight
2020-06-15	Fortgesetzt	Jefferies	Hold
2019-11-08	Herabstufung	Berenberg	Buy → Hold
2019-11-07	Herabstufung	Stifel	Buy → Hold
2019-11-06	Herabstufung	Jefferies	Buy → Hold
2018-11-12	Bestätigt	B. Riley FBR	Buy
2018-01-18	Bestätigt	B. Riley FBR, Inc.	Buy
2017-12-28	Bestätigt	B. Riley FBR, Inc.	Buy
2017-12-04	Hochstufung	Janney	Neutral → Buy
2017-11-08	Hochstufung	Stifel	Hold → Buy
2017-10-19	Eingeleitet	FBR & Co.	Buy
2017-09-19	Herabstufung	Stifel	Buy → Hold
2017-07-17	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-07-14	Eingeleitet	Janney	Neutral
2017-06-01	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-07-18	Herabstufung	Northland Capital	Outperform → Market Perform
2016-07-18	Herabstufung	Piper Jaffray	Overweight → Neutral
2016-02-08	Hochstufung	Jefferies	Hold → Buy
2015-11-05	Bestätigt	Northland Capital	Outperform
2015-10-28	Eingeleitet	Northland Capital	Outperform

Alle ansehen

Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten

Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)

Supernus Pharmaceuticals Inc (SUPN)

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten

Supernus Pharmaceuticals Stock Review: Valuation & Business Quality ConcernsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Supernus at Barclays Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada

To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media

Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Jefferies Financial Group Inc. - MarketBeat

Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Precision Trading with Supernus Pharmaceuticals Inc. (SUPN) Risk Zones - Stock Traders Daily

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc. - MarketBeat

Insider Selling Alert: Georges Gemayel Sells Shares of Supernus Pharmaceuticals Inc (SUPN) - GuruFocus

Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells 10,000 Shares of Stock - MarketBeat

American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Recap Report: Is Supernus Pharmaceuticals Inc being accumulated by smart moneyTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn

Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Buy" at Wall Street Zen - MarketBeat

Assessing Supernus Pharmaceuticals (SUPN) Valuation After Q4 Results And 2026 Guidance Update - Sahm

Citigroup Inc. Lowers Stake in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

GW&K Investment Management LLC Sells 184,268 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan

Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units - Stock Titan

Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units - Stock Titan

Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge? - simplywall.st

Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook - DirectorsTalk Interviews

Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally? - Yahoo Finance

Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus

Supernus at TD Cowen Conference: Strategic Diversification Unveiled By Investing.com - Investing.com South Africa

Supernus at TD Cowen Conference: Strategic Diversification Unveiled - Investing.com

Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses - Quiver Quantitative

Supernus Pharmaceuticals 2025 10-K: $718.95M Revenue, $(0.68) EPS - TradingView

Sage acquisition and ZURZUVAE strategy reshape Supernus (NASDAQ: SUPN) - Stock Titan

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook - simplywall.st

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc. - MarketBeat

Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm

A Look At Supernus Pharmaceuticals (SUPN) Valuation After Record Revenues And 2026 Guidance - simplywall.st

Supernus (SUPN) SVP reports RSU vesting and tax-withholding share disposition - Stock Titan

Supernus (NASDAQ: SUPN) CFO reports RSU vesting and tax share withholding - Stock Titan

SUPERNUS (NASDAQ: SUPN) executive logs RSU grant and tax share withholding - Stock Titan

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2025 Earnings Call Transcript - Insider Monkey

Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns - simplywall.st

Supernus Pharmaceuticals stock hits 52-week high at $57.76 By Investing.com - Investing.com Australia

Supernus (NASDAQ: SUPN) CFO logs RSU vesting, stock awards and tax withholdings - Stock Titan

Director in Supernus (NASDAQ: SUPN) gets 4,475-share stock award - Stock Titan

[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan

Supernus (SUPN) director Carrolee Barlow granted 4,475 common shares - Stock Titan

Supernus (SUPN) SVP gets stock awards, shares withheld for taxes - Stock Titan

Supernus (SUPN) CMO awarded stock as shares withheld for taxes - Stock Titan

TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch - Investing.com Nigeria

Supernus Pharmaceuticals stock hits 52-week high at $57.76 - Investing.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighTime to Buy? - MarketBeat

Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains - Investing.com Nigeria

Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains By Investing.com - Investing.com UK

Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SUPN